SRPT

Top 5 Biotech Stocks That The Smart Money Doesn't Like – Benzinga

Preface: The biotech stocks considered for this review were confined to those over $10 per share that traded at least 500K shares a day based on a 90-day average.For the longest time it seemed that for every new high the S&P 500 hit, biotech stocks, as measured by the iShares Nasdaq Biotechnology Index (NASDAQ: IBB), hit two new highs.Biotechnology […]

Sarepta Therapeutics’s (SRPT) CEO Chris Garabedian Presents at Deutsche Bank Healthcare Conference (Transcript)

[at Seeking Alpha] – Chris Garabedian Yes, thanks Robyn. The guidance we received the couple of weeks ago and we had a conference call on was really what we are waiting for. It had been a long year. We had many interactions … moreView todays social media effects on SRPTView the latest stocks trending across Twitter. Click to view dashboardSee […]

Sarepta Therapeutics’ (SRPT) CEO Chris Garabedian on Q1 2014 Results – Earnings Call Transcript

[at Seeking Alpha] – Chris Garabedian Thank you, Jim. Good morning everyone and thank you for joining us today for our financial and corporate update for the first quarter of 2014. It is proving to be a very exciting year … moreView todays social media effects on SRPTView the latest stocks trending across Twitter. Click to view dashboardSee who Sarepta […]

Sarepta Therapeutics Announces First Quarter 2014 Financial Results and Recent Corporate Developments

[Business Wire] – Sarepta Therapeutics, Inc. , a developer of innovative RNA-based therapeutics, today reported financial results for the three months ended March 31, 2014, and provide moreView todays social media effects on SRPTView the latest stocks trending across Twitter. Click to view dashboardSee who Sarepta is hiring next, click here to view […]